Todd C. Brady
Known title: President and CEOCIK: 0001579179
Todd C. Brady's purchase track record
Todd C. Brady has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/3/2026 | ALDX | $418K | -19.9% | pending | — |
| 6/23/2022 | ALDX | $60K | +60.7% | +80.8% | +0.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ALDX | ▲ Buy | Open Market | 250,000 | $418K | 6/3/2026 | View on chart |
| ALDX | ▼ Sell | Open Market | 85,324 | $260K | 3/12/2024 | View on chart |
| ALDX | ▼ Sell | Open Market | 97,914 | $321K | 3/11/2024 | View on chart |
| ALDX | ▲ Buy | Option Exercise | 192,084 | $106K | 9/7/2023 | View on chart |
| ALDX | ▲ Buy | Option Exercise | 32,953 | $18K | 9/7/2023 | View on chart |
| ALDX | ▲ Buy | Option Exercise | 48,021 | $27K | 9/7/2023 | View on chart |
| ALDX | ▼ Sell | Tax Withholding | 73,807 | $533K | 9/7/2023 | View on chart |
| ALDX | ▲ Buy | Grant | 238,750 | $0 | 2/28/2023 | View on chart |
| ALDX | ▲ Buy | Open Market | 17,700 | $60K | 6/23/2022 | View on chart |
| ALDX | ▲ Buy | Grant | 250,000 | $0 | 3/30/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Biotech Sector News Dominates; No Specific ALDX Updates
Recent news coverage focuses on clinical trial results for other biotechnology companies, such as ACAD and Vertex, rather than Aldeyra Therapeutics. There are no new company-specific announcements or trial updates for ALDX in the provided reports. The stock is currently trading near its 52-week low, reflecting broader sector sentiment rather than isolated corporate news.
Biotech Sector News Dominates; No Specific ALDX Updates. Recent news coverage focuses on clinical trial results for other biotechnology companies, such as ACAD and Vertex, rather than Aldeyra Therapeutics. There are no new company-specific announcements or trial updates for ALDX in the provided reports. The stock is currently trading near its 52-week low, reflecting broader sector sentiment rather than isolated corporate news.